Idexx Laboratories price target raised to $525 from $440 at Stifel

Stifel analyst Jonathan Block raised the firm’s price target on Idexx Laboratories to $525 from $440 and keeps a Hold rating on the shares. Consistent with past quarters, the firm has leveraged third-party visit data, the company’s pricing details and its own analysis, including survey work, to arrive at an estimate for Q4 worldwide CAG Dx recurring revenue growth of 10.5%, which it notes compares favorably to the Street’s 8.1% growth estimate.